Full Text
PCN67 Erlotinib as Second Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)- Economic Modeling (EM) results

Abstract

Authors

E.A.V. Santos C.T. Buschinelli M. Ferracini C. Pepe M. Estanislao

Back to Volume 14, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×